Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10404252" target="_blank" >RIV/00064165:_____/19:10404252 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/19:00112957 RIV/00216208:11110/19:10404252 RIV/00216208:11150/19:10404252 RIV/65269705:_____/19:00072333 and 2 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9Ag5Xwmz4c" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9Ag5Xwmz4c</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.16105" target="_blank" >10.1111/bjh.16105</a>
Alternative languages
Result language
angličtina
Original language name
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
Original language description
Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients. As patient characteristics and disease-related factors change between diagnosis and the initiation of second-line (2L) treatment, an unmet need exists for a tool that can evaluate risk of death at first relapse. We have developed a risk stratification algorithm (RSA) using data from patients with MM who were at 2L. Hazard ratios for independent predictors of overall survival (OS) were derived from a Cox models, and individual patient scores were calculated for total risk. K-adaptive partitioning for survival was used to stratify patients into groups based on their scores. Relative risk doubled with ascending risk group; median OSs for patients in group 1 (lowest risk)-4 (highest risk) were 61 center dot 6, 29 center dot 6, 14 center dot 2 and 5 center dot 9 months, respectively. Differences in OS between risk groups were significant. Similar stratification was observed when the RSA was applied to an external validation data set. In conclusion, we have developed a validated RSA that can quantify total risk, frailty risk and disease aggressiveness risk, and stratify patients with MM at 2L into groups with profoundly different survival expectations.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Haematology
ISSN
0007-1048
e-ISSN
—
Volume of the periodical
187
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
12
Pages from-to
447-458
UT code for WoS article
000480188400001
EID of the result in the Scopus database
2-s2.0-85070532815